The Lancet Review Protocol 11PRT/8142

Following peer review, the Lancet has accepted the CRASH-3 Protocol. Acceptance of the Protocol means that the Lancet has made a provisional commitment to publish the main clinical endpoints of the trial.

The CTU is fully registered as a UK Clinical Research Collaboration (UKCRC) CTU.

This means that we have the capabilities required to provide a full spectrum of expertise required to deliver high quality clinical research to the highest standards.

In order to obtain full registration status we needed to demonstrate:

• Track record and experience of coordinating multi-centre randomised controlled trials or other well designed studies
• Presence of a core team of expert staff to develop studies
• Presence of robust quality assurance systems and processes to meet appropriate regulations and legislation (e.g. the principles of Good Clinical Practice, the NHS Research Governance Framework, the Data Protection Act and the UK regulations that implement the EU Directive for Clinical Trials)
• Evidence of longer term viability of capacity for trials coordination and the development/maintenance of a trials portfolio, including core funding or evidence of a rolling programme of grants, with evidence of commitment from the host institution.

Our aim is to conduct research which improves outcomes relevant to people themselves, as promptly as possible, using the opportunity in all our trials to develop new methods to improve the design, conduct, analysis and dissemination of research studies.The Clinical Trials Unit at LSHTM was formed by combining the two main clinical trials groups in the Faculty of Epidemiology and Population Health: Trials Coordination Group at the Medical Statistics Department (MSD) and the Trials Coordinating Centre at the Department of Nutrition and Public Health Intervention Research (NPHIRU).

We have created a CTU which brings together key opinion leaders and the expertise required for conducting global clinical research in a wide variety of clinical specialties.

If you are interested in joining the CRASH-3 trial, please click on the link below. This will take you to the online Expression of Interest form, where you can enter and submit your details.

Expression of Interest form

Once the form is received the team at the Trial Coordinating Centre will contact you by email as soon as possible.

For your application to be finalised, you will then need to complete a more thorough form, the Hospital information and Principal Investigator CV (HPICV) form.